HI-Bio: A Biogen Company’s Post

We are pleased to share that the acquisition of HI-Bio by Biogen has been completed. Combining our talented teams, complementary capabilities, and scientific expertise, we will be working together to advance our clinical development plans with the goal of delivering innovating treatments to patients with serious unmet needs. Please follow Biogen on LinkedIn for the latest on our work in immune-mediated diseases. Learn more about the acquisition: https://lnkd.in/e_MQqikZ

Last week, members of our team attended the 61st European Renal Association (ERA) Congress in Stockholm. We shared an oral presentation with interim data on our investigational agent felzartamab from the Phase 2 IGNAZ study results in IgA nephropathy (IgAN).   In addition, the final data from a Phase 2 study of felzartamab for late antibody-mediated rejection (AMR) in kidney transplant recipients were presented by lead author Katharina Mayer, M.D., and simultaneously published in the New England Journal of Medicine (NEJM Group). The data demonstrate the promise of our cell-depletion strategy in the treatment of AMR and other immune-mediated diseases.   Thank you to our partners, advisors and everyone who made the conference a success! Read our presentations from the meeting here:   #ERA24 #immunology #nephrology

Today we announced a definitive agreement under which Biogen has agreed to acquire HI-Bio. The proposed acquisition combines expertise in immune-mediated indications with global development and commercial experience in rare diseases. Read more: https://lnkd.in/eQZDrYWd

Today is IgA nephropathy (IgAN) Awareness Day! IgAN is a serious kidney disease, and while categorized as rare, the disease impacts more than 130,000 patients in the U.S. today. We are proud to be working with investigators to advance therapies for patients in need. Thank you to The IgA Nephropathy Foundation for their work to raise awareness and promote research around the disease! #IgANDay #IgANAware

May is #LupusAwarenessMonth and today is #WorldLupusDay, a day dedicated to supporting patients, spreading awareness of and educating people about the disease. At HI-Bio, we’re committed to the development of therapies for rare, immune-mediated diseases (IMDs) including lupus nephritis.    More than 60% of lupus patients will develop lupus nephritis and current treatments have limited efficacy. Through our unique cell depletion strategy, our lead clinical candidate, felzartamab, presents a potential opportunity to treat IMDs like lupus nephritis. We believe that it is critical to focus on the cellular drivers of disease to achieve better outcomes for patients in need. 

Attending European Renal Association (ERA)’s Congress this May? We’ll be sharing oral presentations with data on our investigational agent felzartamab including interim results from the Phase 2 IGNAZ study results in IgA nephropathy (IgAN) and Phase 2 investigator-sponsored study results in antibody-mediated rejection (AMR) in kidney transplant recipients.   See the more details about our abstracts here: https://lnkd.in/e9V85DFB

We are excited to announce that the U.S. Food and Drug Administration has granted orphan drug designation for felzartamab, our investigational agent that is in development for the treatment of antibody-mediated rejection in kidney transplant recipients!   This is an important step forward in our work developing therapies to treat immune-mediated diseases, including rare diseases. Learn more about this important step forward here: https://lnkd.in/eiG8EraB

March is #NationalKidneyMonth and today is #WorldKidneyDay, opportunities for raising awareness around the importance of kidney health. At HI-Bio, we are committed to kidney health and beyond through the development of therapies for rare, immune-mediated diseases (IMDs) including antibody mediated rejection, IgA nephropathy, lupus nephritis, and primary membranous nephropathy.   We are advancing our lead clinical candidate, felzartamab, to potentially treat these IMDs and more through our unique cell depletion approach. By focusing on the cellular drivers of disease, we aim to address patients’ needs and achieve better outcomes.

Today is #RareDiseaseDay, a day dedicated to raising awareness for patients impacted by rare diseases. Rare diseases contribute a meaningful disease burden, and at HI-Bio, we are developing targeted therapies for rare, immune-mediated diseases to provide patients in need with better treatments.    We are committed to the development of our lead clinical candidate, felzartamab, to explore the potential of a cell depletion approach in indications including antibody mediated rejection, IgA nephropathy, lupus nephritis, and primary membranous nephropathy.